Skip to content
OpenCapital
Get started

King Pharmaceuticals KG Q4 2025 Annual earnings

Reported March 13, 2026 · Before market open

Revenue$10.2MMiss by $412.5MDiluted EPS-$1.06Miss by $2.26
Revenue estimate$422.7M
EPS estimate$1.20

Next report

Aug 7, 2026 (In 3 weeks)
Revenue estimate$338.6M

Financials

Q4 2025

Income statement

See full
Revenue$10.2M+737%

Balance sheet

See full
Cash & equivalents$24.6M+475%
Total debt$176.5M+72,218%
Total equity$128.3M+2,685%
Total assets$1.0B+18,229%

Cash flow

See full
Operating cash flow-$65.7M-30,460%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$79.28M—
Enterprise value$231.11M—
P/S2.3×—

Returns & leverage

See full
Debt / equity1.4×+1.3×

Versus estimates

Revenue

Q1 2026$10.2MMiss by $336.3M
Q4 2025$10.2MMiss by $412.5M
Q3 2025$20.3MQ2 2025$546.0K

Diluted EPS

Q1 2026-$1.34
Q4 2025-$1.06Miss by $2.26
Q3 2025-$1.95Q2 2025-$0.72

Ask the moment King Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did King Pharmaceuticals report Q4 2025 earnings?
King Pharmaceuticals (KG) reported Q4 2025 earnings on March 13, 2026 before market open.
What were King Pharmaceuticals's Q4 2025 revenue and EPS?
King Pharmaceuticals reported revenue of $10.2M and diluted EPS of $-1.06 for Q4 2025.
Did King Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $422.7M by $412.5M. EPS missed the consensus estimate of $1.20 by $2.26.
Where can I find King Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-017505) and the 10-K periodic report (0001628280-26-017506) directly on SEC EDGAR. The filing index links above go to sec.gov.